Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Cash from Financing Activities: 2011-2024

Historic Cash from Financing Activities for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to $255.9 million.

  • Ptc Therapeutics' Cash from Financing Activities rose 186.34% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.1 million, marking a year-over-year decrease of 93.52%. This contributed to the annual value of $255.9 million for FY2024, which is 60.42% down from last year.
  • As of FY2024, Ptc Therapeutics' Cash from Financing Activities stood at $255.9 million, which was down 60.42% from $646.4 million recorded in FY2023.
  • Ptc Therapeutics' Cash from Financing Activities' 5-year high stood at $668.7 million during FY2020, with a 5-year trough of $20.9 million in FY2021.
  • Moreover, its 3-year median value for Cash from Financing Activities was $255.9 million (2024), whereas its average is $356.7 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 96.88% in 2021, then surged by 704.48% in 2022.
  • Yearly analysis of 5 years shows Ptc Therapeutics' Cash from Financing Activities stood at $668.7 million in 2020, then slumped by 96.88% to $20.9 million in 2021, then surged by 704.48% to $168.0 million in 2022, then spiked by 284.87% to $646.4 million in 2023, then tumbled by 60.42% to $255.9 million in 2024.